Teysuno

DRUG4 trials

Sponsors

University of Edinburgh, Dutch Colorectal Cancer Group, Shanghai Zhongshan Hospital

Conditions

Bile Duct NeoplasmsCancer of Unknown Primary SiteColorectal CancerGastric CancerGastrointestinal CancerMetastasesPancreatic Cancer

Phase 1

A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Shanghai Zhongshan HospitalGastric Cancer

Start: 2022-06-01End: 2025-12-31Target: 20Updated: 2022-05-31

Phase 2

Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine

CompletedNCT01845337

University of EdinburghBile Duct Neoplasms, Cancer of Unknown Primary Site, Gastrointestinal Cancer +1

Start: 2014-02-05End: 2020-10-08Updated: 2023-05-12

Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Shanghai Zhongshan HospitalGastric Cancer

Start: 2022-06-01End: 2025-05-01Target: 37Updated: 2022-05-26

Phase 3

S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.

CompletedNCT01918852

Dutch Colorectal Cancer GroupColorectal Cancer, Metastases

Start: 2013-12-31End: 2018-03-31Updated: 2018-03-14

Related Papers

Transarterial infusion chemotherapy and embolization (TAICE) as a pre-operative therapy for patients with locally advanced gastric cancer (LAGC): A prospective, single-arm, pilot study.

Journal of Clinical Oncology2025-01-27

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.

2017-06-0157 citations

Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.

Journal of Clinical Oncology2016-05-203 citations